Growing global incidence of substance abuse, increasing cases of prescription diversion, and stringent laws mandating drug screening tests are key factors driving market growth Market Size – USD 1.25 Billion in 2020, Market Growth – at a CAGR of 6.6%, Market Trends – Increasing adoption of urine drug testing at workplaces The global specimen validity testing market size is expected to reach USD 2.10 Billion by 2028 at a CAGR of 6.6%, according to the latest report by Reports and Data.

Clinicians generally order SVT to make informed therapeutic decisions about medical conditions of their patients, which also includes therapeutic overuse and illicit drug abuse.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/4098Some Key Highlights From the Report:Reagents, calibrators, and controls segment is expected to account for largest revenue share among the products segment.

Growth can be attributed to increasing demand and repeated purchase of reagents due to rising number of specimens being tested in drug screening laboratories.Laboratory testing segment is expected to register robust revenue CAGR over the forecast period owing to increasing drug testing in established healthcare facilities, rising cases of drug abuse, and implementation of standardized specimen validity testing protocols in laboratories.Workplace segment is expected to register significant revenue growth over the forecast period owing to rising incidence of drug abuse at workplaces and increasing number of offices and organizations mandating workplace drug screening.North America is expected to account for largest revenue share between 2021 and 2028, attributable to growing use of illicit drugs, increasing incidence of prescription diversion, and presence of stringent laws mandating drug screening in countries in the region.

The key companies profiled in the market are: Thermo Fisher Scientific, Inc., Sciteck, American Bio Medica Corporation, Alere, Express Diagnostics, Premier Biotech, LabCorp., Quest Diagnostics, Alere Toxicology, ACM Global Laboratories, Clinical Reference Laboratory (CRL), SureHire, and CannAmm.For the purpose of this report, Reports and Data has segmented the global specimen validity testing market based on product & services, type, end-use, and region:  Product & Services Outlook (Revenue, USD Billion; 2018-2028)ProductsReagents, Calibrators, & ControlsAssay KitsDisposableServicesType Outlook (Revenue, USD Billion; 2018-2028)Laboratory TestingRapid/POC TestingEnd-use Outlook (Revenue, USD Billion; 2018-2028)       WorkplacesDrug Screening LaboratoriesLaw Enforcement AgenciesPain Management CentresDrug Rehabilitation CentresOthers Browse Complete Report “Specimen Validity Testing Market” @ https://www.reportsanddata.com/report-detail/specimen-validity-testing-marketThe report further segments the market on the basis of key regions of the world and offers an assessment of the production and manufacturing capacity, import and export, production and consumption patterns, supply and demand ratio, and the presence of key players in each region.

In-depth regional analysis covers: North AmericaU.S.CanadaMexicoEuropeGermanyU.K.FranceBENELUXRest of EuropeAsia PacificChinaJapanSouth KoreaRest of APACLatin AmericaBrazilRest of LATAMMiddle East & AfricaSaudi ArabiaA.E.Rest of MEAThe report includes primary and subjective research with a comprehensive study examined and validated by industry professionals and experts.

Market Size – USD 3,004.6 Million in 2018, Market Growth - CAGR of 18.2%, Market Trends – Product launches and research for advanced teleradiology practices According to the current analysis of Reports and Data, the global Teleradiology market was valued at USD 3,004.6 million in 2018 and is expected to reach USD 11,423.4 million by the year 2026, at a CAGR of 18.2%.

Teleradiology is the process of transference of radiological patient images from one place to another for either official diagnosis or consultation with other radiologists and physicians.

Digital image processing methods and sundry wireless technology can provide immense benefits to this market globally.The growing number of imaging tests, rising R activities related to eHealth, and increasing implementation of picture archiving and communication systems are some of the factors estimated to stimulate the growth of the market.

Given the saturated nature of the outsourced, preliminary teleradiology market and the need for large teleradiology companies to grow, the companies’ focus has recently expanded to the acquisition of existing hospital radiology contracts.

Virtual Radiologic (vRad), a major national teleradiology firm, recently announced that it would cut the pay of its contracted radiologists.

It is used by urgent care clinics, hospitals, and mobile imaging companiesThe growing number of imaging tests, rising R activities related to eHealth, and increasing implementation of picture archiving and communication systems are some of the factors boosting the growth of the marketSiemens Healthineers, in collaboration with GE Healthcare, launched a Go platform cardiac CT scanner in March 2019, boosting demand from Hospitals and ClinicsGrowing target population base coupled with the increasing prevalence of chronic diseases, such as cancer, cardiac diseases, bone impairments, and liver diseases, are the major factors contributing to the North American region’s largest revenue share of nearly 40% of the marketDiagnostic centers are expected to high CAGR during the forecast periodX-rays are the leading technique sub- segment of the global teleradiology market with a large market share of 41.1%, as it is having wide applications in various healthcare domains, such as orthopedics, cardiovascular diagnostics, chest imaging, cancer screening, and dental imagingContinuous advancements in medical diagnostic technologies are expected to provide lucrative opportunities for the growth of the teleradiology players during the forecast periodThe key companies profiled in the market are: Siemens AG, Teleradiology Solutions (TRS), Global Diagnostics Limited., Mednax, Inc., Onrad, Inc., Telediagnostics Services Pvt.

The Global Cardiac Arrhythmias Monitoring Devices Market is forecast to reach USD 8.78 Billion by 2026, according to a new report by Reports and Data.Various factors have contributed to the market growth of the industry.

Such improvements enhance the applicability and ease of use of these devices, which in turn have a positive impact on the sector.In addition to that, cardiac arrhythmias monitoring devices also have diverse applicability apart from recording the heartbeat, like alerting the care providers in case of emergencies.

Such varied applicability of these devices also results in promoting the sector and contributes to its market growth.In context to region, North America holds the largest market share because of the easy availability of technologically advanced arrhythmia-monitoring devices in this region and an increase in the prevalence of cardiac arrhythmias.

The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.The key companies profiled in the market are: iRhythm Technologies, Applied Cardiac Systems, Medtronic, Biotelemetry, Welch Allyn, Cardiac Science Corporation, Fukuda Denshi, Preventice Solutions, St.Jude Medical, Spacelabs Healthcare, Nihon Kohden Corporation, NUUBO Smart Solutions Technologies, and AliveCor.Further key findings from the report suggestAvailability of low-cost ECG services and devices is having a positive impact on the growth of the sector.Increased awareness level about cardiac health and arrhythmias is also boosting the growth of this industry.In regards to devices, the resting ECG devices segment is leading the market and is forecasted to occupy 37% of the market share by 2026 with a CAGR of 7.2% during the forecast period.

The reason for this segment to lead the market is applicability in detecting arrhythmias in an individual is in a resting position, making it applicable in hospital admissions.Constant focus on technological advancement in the monitoring devices segment is also boosting the growth rate of the industry.In regards to the technology segment, digital health technology holds the largest market share of 36% in the year 2018, with a growth rate of 6.9% during the forecast period.

Factors contributing to its market share are a long association in the healthcare industry and its applicability in transferring data that helps in managing the health condition.In context to the distribution channel, the dominance of retail pharmacies is observable that holds 69% of the market in 2018, and it is forecasted to witness a growth rate of 6.7%.

Increasing prevalence of chronic diseases, rising geriatric population, growing number of unmet medical needs, increasing evidences of neurological diseases, rising demand for minimally invasive surgeries are key factors contributing to high CAGR of Neurostimulation Devices during forecast period.Market Size – USD 4.98 Billion in 2018, Market Growth - CAGR of 12.4%, Market Trends – Product launches and research for advanced Neurostimulation Devices According to the current analysis of Reports and Data, the global Neurostimulation Devices market was valued at USD 4.98 Billion in 2018 and is expected to reach USD 12.7 Billion by the year 2026, at a CAGR of 12.4 %.

Neurostimulation Devices - Neurostimulator or Neurostimulation are equipment that is used for neuromodulation.

The process of making use of an implantable medical device to alter and modulate neural activities for therapeutic purposes is called neuromodulation.

The recent emergence of Neurostimulation Devices as a neural activity modulator is a major disruptive finding in the healthcare sector.

For instance, Medtronic plc US-based medical device company launched EnterraII gastric neurostimulator, a programmable device that generates mild electrical pulses for gastric electrical stimulation to treat chronic, intractable nausea and vomiting due to gastroparesis.Rising prevalence of chronic diseases and lifestyle health disorders, unmet needs of patients are pushing the technological development, significant focus of healthcare companies on development of novel mechanisms, upcoming patent expiry, availability of private as well public funds for research, and affirmative regulatory scenario all over the globe, are some of the notable factors boosting market growth in the industry.

The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.The key companies profiled in the market are: Medtronic PLC, BioControl Medical, St. Jude Medical, Spinal Modulation, Boston Scientific Corp., Synapse Biomedical Inc., Cochlear, Cyberonics, Inc., and Nevro Corp.Further key findings from the report suggestNeurostimulation Devices market is growing at a CAGR of 13.6% in the Asia Pacific, followed by North America and Europe, with 12.3 % and 12.1% CAGR, respectively.

Rapid Urbanization and digitization, advent of technologies like Internet of Things and cloud services, increase in interface points, ability to manage workflow and increase efficiency, maximum workforce utilization, and extensive research & development are some of the factors, which are expected to grow the Medical Scheduling Software market.Market Size – USD 224.8 million in 2018, Market Growth - CAGR of 12.7%, Market Trends – Incorporation of IT in healthcare, and changing lifestyle in developing countries According to the current analysis of Reports and Data, the global medical scheduling software market was valued at USD 234.8 million in 2018 and is expected to reach USD 612.5 million by the year 2026, at a CAGR of 12.7%.

Thus, any error committed in the clinical services or by healthcare providers might lead to defects or may be fatal.

Therefore, FDA has issued guidelines to inform manufacturers, distributors, and other entities under the purview of FDA, to provide clarity and predictability to software manufacturers.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2131The report provides a complete analysis of the global Medical Scheduling Software  market with important details about the key market players from insightful primary and secondary research data.

Further key findings from the report suggestMedical scheduling software market is growing at a CAGR of 22.7% in Asia Pacific, followed by North America and Europe, with 37.4% and 29.1% CAGR respectively.Advent of technologies like the Internet of Things has helped the growth of the medical scheduling software market, as increased connectivity and number of interface points has facilitated the development of robust medical scheduling software solutions.Parallel growth in the number of Small and Medium Scale Enterprises being set up across the various end-user industries has helped the medical scheduling software market expand.Governments are launching various server-based services in their countries and digitizing their existing services for ease of availing these public services and increase revenue.

This is expected to supplement the growth of the medical scheduling software market.Technological advances in the field of healthcare IT has dramatically changed the healthcare services.

The flexibility of online scheduling software broadens its utility for a variety of different services and activities at medical, healthcare and wellness facilities, such as scheduling patient appointments, treatments, and services.Although other alternatives exist for managing the appointment-booking process, online scheduling software is undoubtedly the most efficient and affordable option for all-sized organizations, regardless of the type of service they schedule.The time constrain and change in lifestyle is contributing to the growth of market as individuals hardly have time to spare for traditional booking methods.

Key factors contributing to the high CAGR are increasing prevalence of diabetes and lack of awareness.

Further, aspects such as technological progressions, product launches and collaborations are fueling the market growth of diabetes devices.Market Size – USD 21.93 Billion in 2018, Market Growth – CAGR of 7.3%, Market Trends – Product Launches and Research for Advanced Tech Developments  Based on current analysis, the global diabetes devices market was valued at USD21.93 billion in 2018 and is expected to reach USD 38.53 billion by 2026, at a CAGR 7.3% Rising awareness about therapeutics for diabetes and diabetes management among patients is strengthening growth of the market.

Continuous technological developments and advancements in the product is another factor expected to create potential opportunities in the market and continue over the forecast period.

This information helps us to understand that diabetes market is growing at an increasing rate due to market drivers mentioned above.

The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.The key companies profiled in the market are: Medtronic, Insulet, Dexcom, Sanofi, Tandem, Ypsomed, Eli Lilly, Bayer Healthcare AG, Becton Dickinson and Company, Novo Nordisk A/S, Abbott Laboratories, F. Hoffman-La Roche AG and Johnson & Johnson.Key findings from the reportAsia-Pacific is anticipated to grow enormously at CAGR of 8.2% during the forecast period, owing to factors, such as a high prevalence of diabetes, growing obese population, and government initiatives of raising awareness regarding diabetic careMedtronic PLC received the US Food and Drug Administration (FDA) approval for Guardian (TM) Connect continuous glucose monitoring (CGM) system, for people with diabetes aged between 14-75 years.

such market initiatives are proving to be profitable for the growth of diabetes device marketGlucose monitoring devices dominated the diabetes devices market by registering 52% of market share in diabetes device productsExpansion of the global diabetes management devices market is also supported by prominent investments, scope of infiltration in middle- and low-income regions and increasing awareness in patient population about effective diabetes control and thus preclusion of disease related complicationsOpportunities for global diabetes device market are adding up due to development of artificial pancreas and development of home infusion therapy.

Global In-Vitro Diagnostics (IVD) Quality Control Market Forecast to 2028 encompasses crucial data about the global In-Vitro Diagnostics (IVD) Quality Control market and includes a thorough examination of technological development, market drivers, market share, market size, and regional segmentation.

The report also provides a comprehensive evaluation of the market trends, vital statistical data, accurate market estimations, and the key suppliers and manufacturers of the In-Vitro Diagnostics (IVD) Quality Control market.The report is also attuned with the currently ongoing COVID-19 pandemic and its effect on the key segments of the market.

The report is updated with the impact of COVID-19 crisis, economic landscape, and present and future impact of COVID-19 on the market.

The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.The key companies profiled in the market are: Abbott Laboratories Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Siemens Healthineers, Randox Laboratories Ltd., Technopath Clinical Diagnostics, Fortress Diagnostics, Roche Diagnostics, Bio-Techne Corporation, Danaher Corporation, SeraCare Life Sciences Inc.The report also covers a comprehensive analysis of the strategic alliances such as mergers and acquisitions, joint ventures, partnerships, collaborations, agreements, government and corporate deals, and product launches and brand promotions.

The report also offers a thorough analysis of the product portfolios, production capacity, gross margins, revenues, and costing of the key manufacturers and vendors.

Furthermore, it also covers SWOT analysis and Porter’s Five Forces Analysis to offer a deeper insight into the competitive landscape of the market.By Product & Service Type (Revenue, USD Million; 2018-2028)Quality Control ProductsWhole Blood-based ControlsSerum/Plasma-based ControlsUrine-based ControlsData Management SolutionsQuality Assurance ServicesSource-based IVD Quality ControlsBy Manufacturer (Revenue, USD Million; 2018-2028)Third-Party Control ManufacturersOriginal Equipment Manufacturers (OEMs)Instrument-Specific ControlsIndependent ControlsBy Application (Revenue, USD Million; 2018-2028)Immunochemistry/ImmunoassayCoagulation & HemostasisMolecular DiagnosticsClinical ChemistryMicrobiologyHematologyOthersBy End-user (Revenue, USD Million; 2018-2028)HospitalsHome CareClinical LaboratoriesAcademic & Research InstitutesContract Research Organizations (CROs)IVD ManufacturersOthersBrowse Complete Report “In-Vitro Diagnostics (IVD) Quality Control Market” @ https://www.reportsanddata.com/report-detail/in-vitro-diagnostics-ivd-quality-control-marketThe report further segments the market on the basis of key regions of the world and offers an assessment of the production and manufacturing capacity, import and export, production and consumption patterns, supply and demand ratio, and the presence of key players in each region.

Growth in chronic diseases, increasing investments by governments, and advancements in technology are driving the market for Ultrasound.Market Size – USD 6.34 Billion in 2018, Market Growth - CAGR of 5.6%, Market Trends – Increasing prevalence of cancer.

The global Ultrasound Market is forecasted to reach USD 10.44 Billion by 2027, according to a new report by Reports and Data.

The demand for ultrasound imaging is expected to rise owing to high demand for early detection of diseases and minimization of the cost of treatments.The government in Europe is focusing on supporting and promoting industrial research.

It has provided several tax incentives to establish R units, with high technologically advanced ultrasound facilities.

The growing trend of ambulatory care is driving the demand for this device.Rising incidence of obesity, unhealthy food consumption, and stressed lifestyle increase the odds of a cardiac related issues.

Rise in minimally invasive surgical and diagnostic procedures and growing number of hospitals are propelling the segment demand.

Rising healthcare expenditure coupled with the increasing research and developments by companies for reducing the complexities in protein labeling are key factors contributing to high CAGR of Protein Labeling market during the forecast period.Market Size – USD 1396.6 Million in 2018, Market Growth - CAGR of 11.8%, Market Trends – Product launches and research for advanced Protein Labeling According to the current analysis of Reports and Data, the global Protein Labelling market was valued at USD 1396.6 Million in 2018 and is expected to reach USD 3544.9 Million by the year 2026, at a CAGR of 11.8%.

The three commonly used tags attach to the protein sequence are stable isotopes, mass tags, and fluorophores.

The companies are focusing on reducing the complexities in the protein labeling process by improving the existing technologies.

The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.The key companies profiled in the market are:Thermo Fisher Scientific, Merck KGaA, PerkinElmer, General Electric company, F. Hoffmann-La Roche and New England Biolabs among othersFurther key findings from the Protein Labeling Market report suggestBiological fluorophores and organic dyes are extensively used for protein labeling; they are suitable for detection of protein location, identification of protein complex and in monitoring biological processes as they respond directly to light by producing a detectable signal.Kits segment is expected to witness the fastest growth at the CAGR of 12.3 %.

Ready to use kits offer a convenient way to label proteins and antibodies.Based on the product, the services segment is expected to grow significantly on account of increased outsourcing of technical and skilled workflow procedures.Asia-Pacific regional segment of the Protein Labelling market is expected to remain highest growing segment during 2019-2026, at a CAGR of 13.1%; owing it to development in various streams such as proteomics, cancer proteomics, immunodynamics, and structural genomics in the region.The scarcity of skilled professionals and limited applications of protein-labeling is likely to hinder the market growth during the forecast periodMajor players are involved in launch of novel products and acquisition and amalgamations of smaller emerging entities to strengthen their market position.

Expanding geographic reach and enhancing product portfolio are some other strategies adopted by larger companies to increase their market share.For the purpose of this study, Reports and Data have segmented the market on the basis of form, routes of administration, product, application, source, end user and regional analysis.

The global Ophthalmic Devices Market is forecast to reach USD 65.60 Billion by 2027, according to a new report by Reports and Data.

Ophthalmology devices are primarily used for the treatment of various eye conditions and infections.As these devices help lowers the treatment time and provide quality eye care to patients, they also assist in making the eye-treatment process more convenient for patients and ophthalmologists.

The rising focus of people on healthcare, continuous developments in the field of medical devices and an increase in investments in healthcare by the government is expected to drive the market in the coming years.The emergence of robots in the field of ophthalmology is growing.

Robotic technologies such as da Vinci Surgical System are integrated into the field of ophthalmology and are assisting surgeons in complex eye surgeries.

The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.The key companies profiled in the market are: Bausch + Lomb, Johnson & Johnson, Alcon, Topcon, Carl Zeiss Meditec, Essilor, Nidek, Haag-Streit, Ziemer Ophthalmic Systems, and Staar Surgical,Further key findings from the report suggestSurgical devices include vitreoretinal surgery devices which are used to treat ophthalmic diseases such as macular degeneration, retinal detachment, vitreous hemorrhage, and others.

This damage is generally caused by an abnormally high pressure in one's eye.Hospitals dominated the market for ophthalmic devices.

Market Size – USD 540 Million in 2019, Market Growth - CAGR of 30.8%, Market Trends – The rising number of trails exploring the use of Hydroxychloroquine in COVID-19 treatment The Global Hydroxychloroquine market is forecasted to reach USD 5.54 Billion by 2027, according to a new report by Reports and Data.

The COVID-19 Impact: Since the outbreak of COVID-19 increasing number of studies being conducted on identifying ways controlling the outbreak.

Based on these findings, on 21 March 2020, President Trump made a tweet claiming that this antimalarial in combination with chloroquine holds the potential to be the major game-changer in the medical history.

The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.The key companies profiled in the market are: Hikma Pharmaceuticals PLC, Cadila Healthcare Ltd, Ipca Laboratories Ltd, Novartis AG, Mylan N.V, Sanofi S.A., Taj Pharmaceuticals Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, Torrent Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and Zydus Cadila.Further key findings from the report suggestIn context to Product Type, the Injection segment is projected to witness a considerable growth rate of 31.2% during the forecast period.

The fact that a large number of patients with malaria and COVID-19 are admitted to hospitals for treatment results in high preference and dependence on this distribution channel for availing the medicine, contributing to the market share held by this segment.In context to Application, the COVID-19 segment is projected to witness the fastest growth rate of 36.0% during the forecast period.

The focus of the study was to endorse the study on stopping COVID-19 using the medication.

Growing global incidence of substance abuse, increasing cases of prescription diversion, and stringent laws mandating drug screening tests are key factors driving market growth Market Size – USD 1.25 Billion in 2020, Market Growth – at a CAGR of 6.6%, Market Trends – Increasing adoption of urine drug testing at workplaces The global specimen validity testing market size is expected to reach USD 2.10 Billion by 2028 at a CAGR of 6.6%, according to the latest report by Reports and Data.

Clinicians generally order SVT to make informed therapeutic decisions about medical conditions of their patients, which also includes therapeutic overuse and illicit drug abuse.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/4098Some Key Highlights From the Report:Reagents, calibrators, and controls segment is expected to account for largest revenue share among the products segment.

Growth can be attributed to increasing demand and repeated purchase of reagents due to rising number of specimens being tested in drug screening laboratories.Laboratory testing segment is expected to register robust revenue CAGR over the forecast period owing to increasing drug testing in established healthcare facilities, rising cases of drug abuse, and implementation of standardized specimen validity testing protocols in laboratories.Workplace segment is expected to register significant revenue growth over the forecast period owing to rising incidence of drug abuse at workplaces and increasing number of offices and organizations mandating workplace drug screening.North America is expected to account for largest revenue share between 2021 and 2028, attributable to growing use of illicit drugs, increasing incidence of prescription diversion, and presence of stringent laws mandating drug screening in countries in the region.

The key companies profiled in the market are: Thermo Fisher Scientific, Inc., Sciteck, American Bio Medica Corporation, Alere, Express Diagnostics, Premier Biotech, LabCorp., Quest Diagnostics, Alere Toxicology, ACM Global Laboratories, Clinical Reference Laboratory (CRL), SureHire, and CannAmm.For the purpose of this report, Reports and Data has segmented the global specimen validity testing market based on product & services, type, end-use, and region:  Product & Services Outlook (Revenue, USD Billion; 2018-2028)ProductsReagents, Calibrators, & ControlsAssay KitsDisposableServicesType Outlook (Revenue, USD Billion; 2018-2028)Laboratory TestingRapid/POC TestingEnd-use Outlook (Revenue, USD Billion; 2018-2028)       WorkplacesDrug Screening LaboratoriesLaw Enforcement AgenciesPain Management CentresDrug Rehabilitation CentresOthers Browse Complete Report “Specimen Validity Testing Market” @ https://www.reportsanddata.com/report-detail/specimen-validity-testing-marketThe report further segments the market on the basis of key regions of the world and offers an assessment of the production and manufacturing capacity, import and export, production and consumption patterns, supply and demand ratio, and the presence of key players in each region.

In-depth regional analysis covers: North AmericaU.S.CanadaMexicoEuropeGermanyU.K.FranceBENELUXRest of EuropeAsia PacificChinaJapanSouth KoreaRest of APACLatin AmericaBrazilRest of LATAMMiddle East & AfricaSaudi ArabiaA.E.Rest of MEAThe report includes primary and subjective research with a comprehensive study examined and validated by industry professionals and experts.

The growth of the market is driven by the increased R investment in the healthcare industry and rising acceptance of cannabis globally.Market Size – USD 1.04 Billion in 2018, Market Growth - CAGR of 27.7%, Market Trends – Increased R investment in the healthcare industry and rising acceptance of cannabis globally.

The market is primarily driven by the increase in the usage of cannabidiol (CBD) in medical application, supplements, beverages and skin care.As a wide-spectrum pharmaceutical therapy, the cannabidiol market place is likely to witness significant R investments in the pharmaceutical industry.

For its potential in the treatment of a number of diseases, multiple scientific studies have shown promising results of cannabidiol.

The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.The key companies profiled in the market are:CV Sciences (US), Isodiol International (Canada), Medical Marijuana (US), Aurora Cannabis (Canada), CBD American Shaman (US), Canopy Growth Corporation (Canada), IRIE CBD (US), The Supreme Cannabis Company (Canada), General Cannabis Corp. (US), Cannabis Sativa, Inc. (US), and Insys Therapeutics, Inc (US).Further key findings from the report suggestThe Cannabidiol (CBD) Market is forecasted to grow from USD 1.04 Billion in 2018 to USD 16.32 Billion by 2026, at a CAGR of 27.7%, during the forecast period.

Due to its health benefits that help in the treatment of neuropsychiatric disorders, the therapeutic grade dominates the segment.

Because of the increasing incidence of physiological disorder among people, especially young adults, fibromyalgia leads the segment.

Growing global incidence of substance abuse, increasing cases of prescription diversion, and stringent laws mandating drug screening tests are key factors driving market growth Market Size – USD 1.25 Billion in 2020, Market Growth – at a CAGR of 6.6%, Market Trends – Increasing adoption of urine drug testing at workplaces The global specimen validity testing market size is expected to reach USD 2.10 Billion by 2028 at a CAGR of 6.6%, according to the latest report by Reports and Data.

Clinicians generally order SVT to make informed therapeutic decisions about medical conditions of their patients, which also includes therapeutic overuse and illicit drug abuse.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/4098Some Key Highlights From the Report:Reagents, calibrators, and controls segment is expected to account for largest revenue share among the products segment.

Growth can be attributed to increasing demand and repeated purchase of reagents due to rising number of specimens being tested in drug screening laboratories.Laboratory testing segment is expected to register robust revenue CAGR over the forecast period owing to increasing drug testing in established healthcare facilities, rising cases of drug abuse, and implementation of standardized specimen validity testing protocols in laboratories.Workplace segment is expected to register significant revenue growth over the forecast period owing to rising incidence of drug abuse at workplaces and increasing number of offices and organizations mandating workplace drug screening.North America is expected to account for largest revenue share between 2021 and 2028, attributable to growing use of illicit drugs, increasing incidence of prescription diversion, and presence of stringent laws mandating drug screening in countries in the region.

The key companies profiled in the market are: Thermo Fisher Scientific, Inc., Sciteck, American Bio Medica Corporation, Alere, Express Diagnostics, Premier Biotech, LabCorp., Quest Diagnostics, Alere Toxicology, ACM Global Laboratories, Clinical Reference Laboratory (CRL), SureHire, and CannAmm.For the purpose of this report, Reports and Data has segmented the global specimen validity testing market based on product & services, type, end-use, and region:  Product & Services Outlook (Revenue, USD Billion; 2018-2028)ProductsReagents, Calibrators, & ControlsAssay KitsDisposableServicesType Outlook (Revenue, USD Billion; 2018-2028)Laboratory TestingRapid/POC TestingEnd-use Outlook (Revenue, USD Billion; 2018-2028)       WorkplacesDrug Screening LaboratoriesLaw Enforcement AgenciesPain Management CentresDrug Rehabilitation CentresOthers Browse Complete Report “Specimen Validity Testing Market” @ https://www.reportsanddata.com/report-detail/specimen-validity-testing-marketThe report further segments the market on the basis of key regions of the world and offers an assessment of the production and manufacturing capacity, import and export, production and consumption patterns, supply and demand ratio, and the presence of key players in each region.

In-depth regional analysis covers: North AmericaU.S.CanadaMexicoEuropeGermanyU.K.FranceBENELUXRest of EuropeAsia PacificChinaJapanSouth KoreaRest of APACLatin AmericaBrazilRest of LATAMMiddle East & AfricaSaudi ArabiaA.E.Rest of MEAThe report includes primary and subjective research with a comprehensive study examined and validated by industry professionals and experts.

Market Size – USD 2.35 Billion in 2018, Market Growth - CAGR of 7.4%, Market Trends – The increase in the demand for High-Purity Selective Separation The Global Medical Membranes market is forecast to reach USD 4.25 Billion by 2026, according to a new report by Reports and Data.

In cross-flow filtration, it is used for clarification of alcohol without the requirement of any media to act as a filter for eliminating particles from alcohol.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1757Further key findings from the report suggestThe medical membranes market held a market share of USD 2.35 Billion in the year 2018 with a growth rate of 7.4% during the forecast period.In context of Material, the Polysulfone (PSU) & Polyether Sulfone (PESU) segment generated the highest revenue of USD 0.68 Billion in 2018 with a growth rate of 7.6% during the forecast period.

The extensive use of this type of material in the functioning of different end-user industries like pharmaceutical, biotechnology, life sciences, and healthcare sectors contribute to the revenue generated by this segment.In regards to Scope, the Therapeutic use segment yielded a higher revenue of USD 1.57 Billion in 2018 with a growth rate of 6.3% during the forecast period.

In context to Process Technology, the Nanofiltration (NF) segment is projected to witness the fastest growth rate of 8.9% during the forecast period, which is expected to occupy 19.0% of the market by 2026.

The key companies profiled in the market are: Sartorius Ag, Asahi Kasei Corporation, 3M Company, Pall Corporation, Merck Millipore (Emd Millipore), Hangzhou Cobetter Filtration Equipment, Ge Healthcare, Microdyn-Nadir GmbH, Koch Membrane Systems and W. L. Gore & Associates, Inc.For the purpose of this report, Reports and Data have segmented the medical membranes market according to Material, Scope, Process Technology, Application, and RegionMaterial Type Outlook (Revenue, USD Billion; 2016-2026)Polyvinylidene Fluoride (PVDF)Polysulfone (PSU) & Polyether Sulfone (PESU)Polypropylene (PP)Polytetrafluoroethylene (PTFE)Modified AcrylicsOthersScope Type Outlook (Revenue, USD Billion; 2016-2026)Diagnostic useTherapeutic useProcess Technology Type Outlook (Revenue, USD Billion; 2016-2026)Microfiltration (MF)Ultrafiltration (UF)Nanofiltration (NF)OthersApplication Type Outlook (Revenue, USD Billion; 2016-2026)Diagnostic useTherapeutic useHemodialysisPharmaceutical FiltrationIv Infusion & Sterile FiltrationDrug DeliveryOthersBrowse Complete Report “Medical Membranes Market” @ https://www.reportsanddata.com/report-detail/medical-membranes-marketThe report further segments the market on the basis of key regions of the world and offers an assessment of the production and manufacturing capacity, import and export, production and consumption patterns, supply and demand ratio, and the presence of key players in each region.

In-depth regional analysis covers: North AmericaU.S.CanadaMexicoEuropeGermanyU.K.FranceBENELUXRest of EuropeAsia PacificChinaJapanSouth KoreaRest of APACLatin AmericaBrazilRest of LATAMMiddle East & AfricaSaudi ArabiaA.E.Rest of MEAThe report includes primary and subjective research with a comprehensive study examined and validated by industry professionals and experts.

The global Remote Patient Monitoring Market is forecast to reach USD 2.14 Billion by 2027, according to a new report by Reports and Data.

Apart from technological advancements, applicability, and convenience associated with the use of this service, have also acted as a significant contributing factor for this industry.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3234The report provides a complete analysis of the global Remote Patient Monitoring Market market with important details about the key market players from insightful primary and secondary research data.

The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.Further key findings from the report suggestThe remote heart rate monitor gives information on heart rate and sends results to the webserver.

One of the significant reasons for the adoption of this system is the increase in the rate of obesity, which results in cardiovascular diseases [CVD].

Due to the rise in the rate of occurrence of CVD, remote cardiac monitoring services are becoming increasingly relevant for the healthcare sector, which is turning out to be a significant driving factor for this industry.A vast majority, approximately 88% of hospitals have invested in remote patient monitoring technologies as part of their transition to a value-based care model.

North America dominated the market, with a share of 38.3% in the year 2019.The key companies profiled in the market are: Abbott Laboratories, GE Healthcare, Omron Corporation, Medtronic PLC, Boston Scientific Corporation, Biotronik SE & Co. KG, Nihon Kohden Corporation, General Electric Company, Masimo Corporation, and Johnson and Johnson.Browse Complete Report “Remote Patient Monitoring Market Market” @ https://www.reportsanddata.com/report-detail/remote-patient-monitoring-marketFor the purpose of this report, Reports and Data have segmented the global Remote Patient Monitoring Market on the basis of product, application, end-use, and region:Product Outlook (Revenue, USD Billion; 2017-2027)Vital Sign MonitorsPulse OximetersTemperature MonitorBrain Monitoring (EEG)Blood Pressure MonitorsHeart Rate Monitor (ECG)Respiratory Rate MonitorSpecial MonitorsBlood Glucose MonitorsRespiratory MonitorAnesthesia MonitorsCardiac Rhythm MonitorFetal Heart MonitorsMulti-Parameter Monitors (MPM)Prothrombin MonitorsOthersApplication Outlook (Revenue, USD Billion; 2017-2027)Cardiovascular DiseasesCancerSleep DisordersDiabetesWeight management and Fitness MonitoringInfectionsBronchitisDehydrationVirusHypertensionEnd-Use Outlook (Revenue, USD Billion; 2017-2027)Hospital-based patientsHome HealthcareAmbulatory PatientThe report further segments the market on the basis of key regions of the world and offers an assessment of the production and manufacturing capacity, import and export, production and consumption patterns, supply and demand ratio, and the presence of key players in each region.